NCT06151938View on ClinicalTrials.gov

Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

Enrolling by invitationOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

May 20, 2025

Study Completion Date

August 20, 2025

Conditions
Allergic Rhinitis Due to House Dust MiteAllergic Asthma
Interventions
DRUG

Standardised allergen extract from house dust mites

Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.

Trial Locations (1)

571400

Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital), Qionghai

All Listed Sponsors
lead

ALK-Abelló A/S

INDUSTRY